Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies

NCT03248479 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03248479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03248479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
September 8, 2017
Completion date
September 5, 2023
Enrollment
258 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancies